Close Menu

NEW YORK (GenomeWeb) – 23andMe today announced an agreement with drug developer Reset Therapeutics to study the genetics of the circadian clock.

The goal of the collaboration is to develop drug targets for therapeutics that will restore the body's 24-hour physiological rhythms, Reset said in a statement.

Through this collaboration, 23andMe will provide Reset scientists with de-identified, aggregated data from more than 650,000 customers who have consented for their genomic information to be a part of scientific research.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.